A Phase 2 interventional study of Experimental Drug SESC 01 and Placebo in Tinea Pedis, sponsored by South End Skin Care. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-06.
Sponsored by South End Skin Care · Phase 2, Interventional, and Treatment
This is a three-arm randomized controlled trial to assess the efficacy of an experimental treatment in the treatment of tinea pedis (athlete's foot). The experimental treatment will be tested against a vehicle control to determine efficacy and safety, and against an active comparator to evaluate the success of the treatment relative to an existing gold-standard treatment. Patients will be treated for four weeks, with their condition being assessed at the end of treatment and two weeks after the end of treatment. The primary endpoint for this study is effective treatment rate at the week 6 evaluation, defined as a mycological cure and minimal clinical signs \& symptoms. Secondary endpoints include safety and patient evaluation of treatment.
Exclusion Criteria:
Patients supplied with Experimental Drug SESC 01 for daily topical therapy for 4 weeks.
Drug: Experimental Drug SESC 01
Patients supplied with inactive vehicle (placebo), identical to experimental treatment but without active ingredients, to be applied daily for 4 weeks.
Drug: Placebo
Terbinafine hydrochloride cream, to be applied twice daily for 4 weeks.
Drug: Terbinafine Hydrochloride
Topical experimental treatment comprising a combination of approved topical therapies and a new dosage method.
Dosage method of SESC 01, without active ingredients.
Topical terbinafine hydrochloride cream.
Also known as: Lamisil AT
Effective Treatment (Mycological Cure and Minimal Symptoms)
Binary outcome measure defined as mycological cure AND a total clinical assessment score less than or equal to 2 (out of a possible 18). Mycological cure is defined as negative potassium hydroxide microscopy, while the clinical assessment is based on a sum of 6 symptoms (desquamation, vesiculation, erythema, fissuring, maceration, and pruritus) scored 0-3 by a physician.
Time frame: 6 weeks
Rate of Adverse Events
To examine treatment safety, we will calculate the rate of adverse events and serious adverse and compare them between the study's three arms using Chi-square tests to evaluate whether a statistically significant difference is present.
Time frame: 6 weeks
Effective Treatment (Mycological Cure and Minimal Symptoms)
Effective treatment as defined above, but measured at the end of treatment (4 weeks after the beginning of participation).
Time frame: 4 weeks
Patient Satisfaction Score
At the conclusion of treatment, patients complete a brief survey on their impressions of the treatment's tolerability, effectiveness, and convenience on a five-point scale, where 1 = poor, 2 = fair, 3 = good, 4 = very good, 5 = excellent, or they may answer with "No answer/prefer not to say". Scores will be compared for each of the three characteristics and as a sum of the three scores.
Time frame: 4 weeks
Self-Reported Patient Compliance
On the same experience questionnaire, patients are asked to estimate how many doses of treatment they missed or forgot to take. Possible answers are None, 1-2, 3-4, 5-6, 7-8, or 9 or more. This indicates whether there is a significant difference in patients' likelihood to adhere to a treatment regimen.
Time frame: 4 weeks
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.